Prothena Biosciences (PRTA) - Long-Term Liabilities to Capital

Prothena Corporation PLC - graphic logo of issuer PRTA

Prothena Corporation (PRTA) is a leading developer of amyloidosis therapies, creating antibodies to eliminate pathological proteins associated with Parkinson's disease. The available price action vector on GURU.Markets is recorded at 0.01. Business stability is supported by centers in the US and Ireland, which develop Alzheimer's treatments in collaboration with corporate behemoths. However, high volatility persists due to the stock price's dependence on clinical trial outcomes.

Prothena Corporation (PRTA): Long-Term Debt to Equity from 07/04/2022 to 10/29/2026

Analytical breakdowns for Prothena Corporation

- current price and projected stock value:
Share Price Prothena|PRTA - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Prothena Corporation plc|PRTA - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share Prothena|PRTA - Company Book Value|Market Value to Book Value prothena.com|PRTA - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Capital Prothena Corporation|PRTA - Long-Term Debt to Equity|Current Liabilities to Equity Prothena Corp|PRTA - Company Debts|Debt to Net Assets Ratio Prothena Corporation plc|PRTA - Company Long-Term Debt|Short-Term Debt Prothena
Comprehensive company analysis:Prothena Corporation - PRTA
Original product of Prothena

Financial stability is critical for Prothena Corporation (PRTA), a biotechnology company investing in costly R&D and scientist retention through RSUs. The long-term debt-to-equity ratio reflects the proportion of loans with maturities exceeding one year within the equity structure, where low values confirm a conservative financing approach, while an increase indicates the use of leverage to accelerate drug development.

Analysis of competing companies

Long-Term Debt to Capital Ratio BIIB (Biogen Inc)|Long-Term Debt to Capital NBIX|RGC - Long-Term Liabilities to Capital|Axsome Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acadia-pharm.com ACAD|XENE - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Catalyst Corp (CPRX)|Long-Term Debt to Equity Denali Therapeutics|harmonybiosciences.com - Long-Term Liabilities to Equity|Long-Term Debt to Equity Biohaven (BHVN)|AMLX (Amylyx Pharmaceuticals Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Trevi Pharma TRVI|Praxis Corp (PRAX) - Long-Term Liabilities to Capital|AVXL: Long-Term Debt to Equity Ratio|ceribell.com - Long-Term Loans to Capital Ratio|ALEC: Long-Term Debt to Capital|Annexon Biosciences - Long-Term Debt to Capital Coefficient|OMER (Omeros Corp) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Neurogene Therapeutics NGNE|Long-Term Debt to Equity AC Immune (ACIU)|voyagertherapeutics.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital NMRA (Neumora Therapeutics, Inc.)|Long-Term Debt to Capital Scilex Holding SCLX|TVGN: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ACOG (Alpha Cognition)|CGTX: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio inhibikase.com|Long-Term Debt to Equity Cassava Sciences|Long-Term Liabilities to Capital Assertio Therapeutics ASRT|Long-Term Debt to Equity Coya Therapeutics, Inc. (COYA)|VTGN (vistagen.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ovid Therapeutics OVID|ABOS (acumenpharm.com) - Long-Term Liabilities to Equity|CRVO - Long-Term Debt to Equity|Long-Term Liabilities to Capital Alterity Therapeutics|clene.com (CLNN) - Long-Term Debt to Equity|PepGen - Long-Term Debt to Capital Coefficient|JUNS (Jupiter Neurosciences Inc) - Long-Term Debt to Capital|Long-Term Debt to Capital relmada.com|Long-Term Debt to Equity Ratio ANVS (Annovis Bio)|Long-Term Loans to Capital Ratio GRCE|Long-Term Debt to Capital AIFF (Firefly Neuroscience Inc)|Ratio of Long-Term Indebtedness to Capital ANEW Medical (KLTO)|NRSN - Long-Term Debt to Equity|Long-Term Liabilities to Capital revivapharma.com|metaviatx.com (MTVA) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio NRXS|Long-Term Debt to Equity Helius Medical Technologies, Inc.|Passage Bio Corp - Long-Term Liabilities to Equity|Long-Term Debt to Equity Neuphoria Therapeutics Inc. (NEUP)|NERV (minervaneurosciences.com) - Long-Term Debt to Capital Coefficient|Athira Pharma - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio ADXN (Addex Therapeutics Ltd.)|Alzamend - Long-Term Debt to Capital|CYCN - Long-Term Debt to Capital|protagenic.com (PTIX) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio KTTA|CRGT (Cortigent Inc) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Avenue Therapeutics Inc. ATXI|Long-Term Debt to Equity Ratio BCLI (Brainstorm Cell Therapeutics, Inc.)|Long-Term Debt to Capital Cara Therapeutics Inc (CARA)|Long-Term Debt to Equity Chromocell Therapeutics CHRO|Long-Term Debt to Capital Coefficient ELYM|ITCI - Long-Term Debt to Equity|Long-Term Liabilities to Capital Longboard Pharmaceuticals Inc|Marinus (MRNS) - Long-Term Debt to Equity|Long-Term Liabilities to Equity NKGN (NKGen Biotech Corp)|Long-Term Debt to Equity NeuroBo Pharmaceuticals|SAGE: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Synaptogenix (SNPX)|TRVN - Long-Term Liabilities to Capital|Vigil Neuroscience, Inc. - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio WENA (Anew Medical Inc.)|Cerevel Therapeutics - Long-Term Debt to Capital